Pharma Focus Asia
KP - Choose our fully recyclable blister films

Eli Lilly Launch New Drug to Treat Acute Migraine in Adults

A new oral medication, REYVOW™ (lasmiditan) has been launched by Eli Lilly and Company for the treatment of acute migraine, with or without aura, in adults.

The drug, REYVOW is delivered orally via a tablet and is the first serotonin receptor agonist. It binds to (5-HT) 1F receptor with high affinity.

However, its exact mechanism is unknown yet.

The effectiveness of REYVOW was demonstrated in two randomized, double-blind, placebo-controlled trials.

In both the studies, the percentage of patients whose pain had resolved was significantly greater for those taking the medication rather than the placebo.

The treatment-emergent adverse events in the trial were generally mild to moderate and the most frequent included fatigue, dizziness, nausea and/or vomiting, paresthesia, sedation, and muscle weakness.

REYVOW can be prescribed to patients in oral doses of 50mg, 100mg, and 200mg as needed and once available.

The US FDA has given its approval for the drug.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024